Sorrento Therapeutics Announces Dismissal Of Lawsuits

« Back to News

SAN DIEGO, June 14, 2017 /PRNewswire/ -- Sorrento Therapeutics (NASDAQ: SRNE) announced today the dismissal of all claims against Sorrento and its Directors contained in the lawsuits brought by Wildcat Liquid Alpha, LLC.

Sorrento Therapeutics, Inc. (PRNewsFoto/Sorrento Therapeutics, Inc.)

About Sorrento Therapeutics

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for immuno-oncology, inflammation and autoimmune diseases. Sorrento's lead product candidates include immunotherapies focused on the treatment of both solid tumors and hematological malignancies, as well as late stage pain products. For more information, please visit

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.  All other trademarks and trade names are the property of their respective owners.

© 2017 Sorrento Therapeutics, Inc.  All Rights Reserved.


SOURCE Sorrento Therapeutics, Inc.